Crossmark

Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study

Crossref DOI link: https://doi.org/10.1038/s41375-023-01856-6

Published Online: 2023-02-22

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gossai, N. https://orcid.org/0000-0003-1693-4898
Bhojwani, D. https://orcid.org/0000-0002-7559-7927
Schafer, E. S.

Chang, B. H. https://orcid.org/0000-0003-3783-1820
Pommert, L. https://orcid.org/0000-0001-8760-5202
Verma, A. https://orcid.org/0000-0001-6555-7924
Malvar, J.

Chi, Y. Y.

Hitzler, J. https://orcid.org/0000-0003-1158-186X
Burke, M. J. https://orcid.org/0000-0001-6626-2773
Rabin, K. R.
License Information

Text and Data Mining valid from 2023-02-22

Version of Record valid from 2023-02-22
More Information

Article History

Received: 2 October 2022

Revised: 5 February 2023

Accepted: 15 February 2023

First Online: 22 February 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below